ERBB2 and invasive breast carcinoma: Additionally, trastuzumab (anti-HER2 monoclonal antibody) resistance, which is associated with a poorer prognosis, was attenuated in HER2-positive BrCa through HSP90 inhibition [58,67] and could serve as an adverse, independent prognostic biomarker for this malignancy.